Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05342519 · ClinicalTrials.gov registry record · Phase 2
Daily Topical Rapamycin for Vitiligo
A Phase 2 study of Vitiligo, sponsored by Medical University of South Carolina.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05342519: Active Phase 2 study of Vitiligo, sponsored by Medical University of South Carolina.
NCT05342519 is a Phase 2 study of Vitiligo that is active but no longer recruiting, run by Medical University of South Carolina. The registered enrollment target is 20 participants, below the 1,123-participant average among 15 other Vitiligo trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05342519, a Phase 2 study of Vitiligo, is active but no longer recruiting, sponsored by Medical University of South Carolina.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
In current Dermatology practice, options for vitiligo remain limited. The purpose of this study is to determine if once daily dosed topical rapamycin is effective for the treatment of patients with vitiligo. Participants will apply either 0.1% topical rapamycin or 0.001% topical rapamycin for six months to a lesion on one side of the body, and topical placebo to a corresponding lesion on the opposite side of the body. The study also aims to evaluate patient satisfaction and identify any adverse effects on these dosing regimens.
Primary Outcome
Absence of change in appearance of targeted lesion. Vitiligo is a depigmenting disease and treatment responses are graded by percentage of repigmentation on a 5-point scale
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rapamycin
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-07-28 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
What the registry record for NCT05342519 still lists
NCT05342519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,123-participant average among 15 other Vitiligo trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05342519 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT05342519 about?
NCT05342519 is a clinical study titled "Daily Topical Rapamycin for Vitiligo". In current Dermatology practice, options for vitiligo remain limited. The purpose of this study is to determine if once daily dosed topical rapamycin is effective for the treatment of patients with vitiligo. Participants will apply either 0.1% topical rapamycin or 0.001% topical rapamycin for six mo...
What is the current status of trial NCT05342519?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-07-28. Estimated completion is 2027-12-01.
What conditions does trial NCT05342519 study?
This clinical trial studies the following conditions: Vitiligo.
What interventions are being tested in trial NCT05342519?
The interventions under investigation include: Placebo (DRUG), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT05342519?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05342519 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05342519's enrollment target sits among peer trials
20 13th of 15 higher than 3 of 15 other Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
COMPLETED · Phase 2
-
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
COMPLETED · Phase 2
-
Evaluation of AMG 714 for Vitiligo
COMPLETED · Phase 2
-
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
COMPLETED · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI